Cited by 204Liver Disease Diagnosis and TreatmentLiver physiology and pathologyHippo pathway signaling and YAP/TAZ

Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis

Open access
Wang, Xiaobo, Cai, Bishuang, Yang, Xiaoming, Sonubi, Oluwatoni O., Zheng, Ze, Ramakrishnan, Rajasekhar, Shi, Hongxue, Valenti, Luca +11 more·2020·Cell Metabolism

Abstract

Incomplete understanding of how hepatosteatosis transitions to fibrotic non-alcoholic steatohepatitis (NASH) has limited therapeutic options. Two molecules that are elevated in hepatocytes in human NASH liver are cholesterol, whose mechanistic link to NASH remains incompletely understood, and TAZ, a transcriptional regulator that promotes fibrosis but whose mechanism of increase in NASH is unknown. We now show that increased hepatocyte cholesterol upregulates TAZ and promotes fibrotic NASH. ASTER-B/C-mediated internalization of plasma membrane cholesterol activates soluble adenylyl cyclase (sAC; ADCY10), triggering a calcium-RhoA-mediated pathway that suppresses β-TrCP/proteasome-mediated TAZ degradation. In mice fed with a cholesterol-rich NASH-inducing diet, hepatocyte-specific silencing of ASTER-B/C, sAC, or RhoA decreased TAZ and ameliorated fibrotic NASH. The cholesterol-TAZ pathway is present in primary human hepatocytes, and associations among liver cholesterol, TAZ, and RhoA in human NASH liver are consistent with the pathway. Thus, hepatocyte cholesterol contributes to fibrotic NASH by increasing TAZ, suggesting new targets for therapeutic intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2020.03.010

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., Infante, R. E., Radhakrishnan, A., Covey, D. F., Guan, K.-L., Buck, J., Levin, L. R., Tontonoz, P., Schwabe, R. F., & Tabas, I.
Affiliations
  • Columbia University Irving Medical Center (US)
  • Ningxia Medical University (CN)
  • Weill Cornell Medicine (US)
  • University of Milan (IT)
  • University of California, Los Angeles (US)
  • The University of Texas Southwestern Medical Center (US)
  • Washington University in St. Louis (US)
  • University of California San Diego (US)
Corresponding author
  • Wang, Xiaobo
  • Tabas, Ira
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2020-05
Volume
31
Issue
5
Pages
969-986.e7
ISSN
1550-4131 (ISSN-L)
OpenAlex
W3015115032
Cited by
204
References
75
Citations by year
2026: 24 · 2025: 37 · 2024: 31 · 2023: 34 · 2022: 35 · 2021: 29 · 2020: 13
FWCI
19.89
Type
journal article
Language
en
Open access
Locations
  • Cell Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • American Society of Hematology (19CDA34660043)
  • University of Pittsburgh
  • Welch Foundation (DE015964, DK103818, I-1793, HL067773, HL087123, R35CA196878, HL136618, AG061290, HD088571, HL132412, DK119767)
  • University of Minnesota
  • American Heart Association
  • European Commission
  • National Institutes of Health (DK116620, HHSN276201200017C)
  • Associazione Italiana per la Ricerca sul Cancro (16888)
  • National Cancer Institute (P30 CA013696)
  • National Heart, Lung, and Blood Institute (T32HL007343)
  • American Liver Foundation (1K99DK115778, XAB2018AW09)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
Keywords
nonalcoholic steatohepatitis, cholesterol, TAZ, liver fibrosis, soluble adenylyl cyclase, RhoA, calcium signaling, β-TrCP, proteasomal degradation, hepatic steatosis
MeSH terms
Transcriptional Coactivator with PDZ-Binding Motif Proteins, Animals, Cells, Cultured, Cholesterol, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Hepatocytes, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review